KCA
Search
- Page Path
- HOME > Search
Original Articles
- Genitourinary cancer
- Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer
- Hye Won Lee, Eui Hyun Jung, Kyung Hwan Kim, Hong Koo Ha, Jong Jin Oh, Seok Ho Kang, Seung-hwan Jeong, Hyeong Dong Yuk, Ji Eun Heo, Won Sik Ham, Eu Chang Hwang, Seung Il Jung, Wan Song, Bumjin Lim, Bumsik Hong, Byung Chang Jeong, Ho Kyung Seo
- Cancer Res Treat. 2026;58(2):591-602. Published online May 12, 2025
- DOI: https://doi.org/10.4143/crt.2025.100
-
Abstract
PDF
PubReader
ePub - Purpose
This study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC).
Materials and Methods
This retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models.
Results
Patients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course.
Conclusion
Our research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability. -
Citations
Citations to this article as recorded by
- Gemcitabine-Based Bladder Preservation in BCG-Unresponsive High-Risk NMIBC: Evidence, Limitations, and Clinical Positioning
Aris Kaltsas, Konstantinos Papathanasiou, Ilias Giannakodimos, Athanasios Zachariou, Nguyen Phuc Cam Hoang, Mai Ba Tien Dung, Tran Vinh Hung, Michael Chrisofos, Nikolaos Sofikitis, Fotios Dimitriadis
Biomedicines.2026; 14(8): 1821. CrossRef - Factors Associated with Recurrence and Progression Following Intravesical Bacillus Calmette–Guérin Therapy in Intermediate- and High-Risk Non-MuscleInvasive Bladder Cancer: A Five-Year RealWorld Cohort Study
Ali Can Albaz, Muhammet Bilmiş, Talha Muezzinoglu
Acıbadem Üniversitesi Sağlık Bilimleri Dergisi.2026;[Epub] CrossRef
- Gemcitabine-Based Bladder Preservation in BCG-Unresponsive High-Risk NMIBC: Evidence, Limitations, and Clinical Positioning
- 6,739 View
- 274 Download
- 1 Web of Science
- 2 Crossref
- General
- Presentation of Benefits and Harms in Cancer Screening Guidelines for Koreans: A Systematic Review
- Mi Ah Han, Hunju Lee, Kwangmin Kim, Seong Jung Kim, Eu Chang Hwang, Jae Hung Jung
- Cancer Res Treat. 2025;57(4):923-931. Published online March 27, 2025
- DOI: https://doi.org/10.4143/crt.2024.1151
-
Abstract
PDF
Supplementary MaterialPubReaderePub - Purpose
This study systematically reviewed cancer screening guidelines for the Korean population to evaluate the benefits and harms of the recommended cancer screening practices.
Materials and Methods
We searched international electronic databases from inception to July 2023. Two reviewers independently conducted reference screening and data extraction. Data were extracted based on recommendations from each guideline and presentation of benefits and harms. General characteristics of the cancer screening guidelines, including cancer type, recommended screening methods, certainty of evidence, were collected. Moreover, we obtained key information on the benefits and harms of screening interventions, including the quantification of their relative and absolute effects.
Results
Fifteen recommendations were identified for the use of interventions for the early detection of stomach, liver, colorectal, breast, cervical, and lung cancers in nine guidelines published between 2011 and 2015. Seven guidelines collected evidence through de novo systematic reviews. Eight guidelines presented the certainty of evidence and strength of recommendations. Benefits are presented as relative risks, and harms are presented as absolute risks. Six recommendations presented the absolute effects of both benefits and harms (comparable); eight presented them unevenly, including quantifying benefits relatively but presenting harms as absolute measures (asymmetric); and one presented neither benefits nor harms (incomplete).
Conclusion
More than half of guidelines fail to present the benefits and harms of screening in a balanced manner. To enable users and beneficiaries make informed decisions based on evidence, the benefits and harms supporting recommendations should be given in a transparent and balanced manner.
- 4,496 View
- 153 Download
- Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry
- Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung, Korean Renal Cell Carcinoma Study Group
- Cancer Res Treat. 2019;51(2):758-768. Published online September 7, 2018
- DOI: https://doi.org/10.4143/crt.2018.421
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein.
Materials and Methods
From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS).
Results
The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median firstline PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS.
Conclusion
The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC. -
Citations
Citations to this article as recorded by- International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma
Alessandro Rametta, Sebastiano Buti, Marco Stellato, Marco Maruzzo, Luca Lalli, Alessandro Acunzo, Michele Maffezzoli, Davide Bimbatti, Francesco Pierantoni, Francesco Massari, Paola Ermacora, Roberto Iacovelli, Alessia Mennitto, Claudia Mucciarini, Matte
Tumori Journal.2026; 112(4): 297. CrossRef - Current Evidences and Future Perspectives in the Management of Metastatic Non‐Clear Cell Renal Cell Carcinoma
Shotaro Nakanishi, Junichi Inokuchi
International Journal of Urology.2025; 32(9): 1118. CrossRef - Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer
Merve KESKİNKILIÇ, Kübra CANASLAN, Hüseyin Salih SEMİZ, Tuğba YAVUZŞEN
Forbes Journal of Medicine.2025; 6(2): 180. CrossRef - Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist
Angelo Del Gaudio, Loris Riccardo Lopetuso, Valeria Pavese, Erica Palesandro, Ilaria Campisi, Marcello Tucci, Franco Scaldaferri
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef - Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
International Journal of Cancer.2024; 154(6): 947. CrossRef - Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study
Joongwon Choi, Seokhwan Bang, Jungyo Suh, Chang Il Choi, Wan Song, Hyeong Dong Yuk, Chan Ho Lee, Minyong Kang, Seol Ho Choo, Jung Kwon Kim, Hyung Ho Lee, Jung Ki Jo, Eu Chang Hwang, Chang Wook Jeong, Young Hwii Ko, Jae Young Park, Cheryn Song, Seong Il Se
Scientific Reports.2024;[Epub] CrossRef - Prognostic Factors and Treatment Outcomes in Renal Cell Carcinoma: A Comprehensive Analysis
Ömer Faruk ELÇİÇEK, Mehmet KÜÇÜKÖNER
Namık Kemal Tıp Dergisi.2024; : 217. CrossRef - High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet?
Fady Sidhom, Shefali Patel, Arpita Desai, Arnab Basu
Clinical Genitourinary Cancer.2024; 22(6): 102235. CrossRef - Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database
Jung Kwon Kim, Sangchul Lee, Sung Kyu Hong, Cheol Kwak, Chang Wook Jeong, Seok Ho Kang, Sung-Hoo Hong, Yong-June Kim, Jinsoo Chung, Eu Chang Hwang, Tae Gyun Kwon, Seok-Soo Byun, Yu Jin Jung, Junghyun Lim, Jiyeon Kim, Hyeju Oh
Scientific Reports.2023;[Epub] CrossRef - Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
Shawna R. Calhoun, Manish Sharma, Chung-Han Lee
Kidney Cancer.2023; 7(1): 123. CrossRef - A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy
Sung Han Kim, Jongkeun Park, Weon Seo Park, Dongwan Hong, Jinsoo Chung
Investigative and Clinical Urology.2022; 63(6): 602. CrossRef - Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
Ilya Tsimafeyeu, Oxana Shatkovskaya, Sergei Krasny, Nurzhan Nurgaliev, Ilya Varlamov, Vladislav Petkau, Sufia Safina, Ruslan Zukov, Mikhail Mazhbich, Galina Statsenko, Sergey Varlamov, Olga Novikova, Igor Zaitsev, Pavel Moiseyev, Alexander Rolevich, Alesy
Cancer Reports.2021;[Epub] CrossRef - The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results
Ismail Selvi, Umut Demirci, Nazan Bozdogan, Halil Basar
International Urology and Nephrology.2020; 52(1): 21. CrossRef - Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study
I. V. Tsimafeyeu, I. S. Varlamov, V. V. Petkau, S. Z. Safina, R. A. Zukov, M. S. Mazhbich, G. B. Statsenko, S. A. Varlamov, I. V. Zaitsev, O. Yu. Novikova, S. А. Krasny, N. S. Nurgaliyev, I. L. Popova, L. Yu. Vladimirova
Malignant tumours.2019; 9(2): 45. CrossRef
- International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma
- 14,292 View
- 247 Download
- 15 Web of Science
- 14 Crossref
- Poor Preoperative Glycemic Control Is Associated with Dismal Prognosis after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Korean Multicenter Study
- Sung Gu Kang, Eu Chang Hwang, Seung Il Jung, Ho Song Yu, Ho Seok Chung, Taek Won Kang, Dong Deuk Kwon, Jun Eul Hwang, Jun Seok Kim, Joon Hwa Noh, Jae Hyung You, Myung Ki Kim, Tae Hoon Oh, Ill Young Seo, Seung Baik, Chul-Sung Kim, Seok Ho Kang, Jun Cheon
- Cancer Res Treat. 2016;48(4):1293-1301. Published online March 23, 2016
- DOI: https://doi.org/10.4143/crt.2016.021
-
Abstract
PDFPubReaderePub
- Purpose
The purpose of this study is to evaluate the effect of diabetes mellitus (DM) and preoperative glycemic control on prognosis in Korean patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU). Materials and Methods A total of 566 patients who underwent RNU at six institutions between 2004 and 2014 were reviewed retrospectively. Kaplan-Meier and Cox regression analyses were performed to assess the association between DM, preoperative glycemic control, and recurrence-free, cancer-specific, and overall survival.
Results
The median follow-up period was 33.8 months (interquartile range, 41.4 months). A total of 135 patients (23.8%) had DM and 67 patients (11.8%) had poor preoperative glycemic control. Patients with poor preoperative glycemic control had significantly shorter median recurrence-free, cancer-specific, and overall survival than patients with good preoperative glycemic control and non-diabetics (all, p=0.001). In multivariable Cox regression analysis, DM with poor preoperative glycemic control showed association with worse recurrence-free survival (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.31 to 3.90; p=0.003), cancer-specific survival (HR, 2.96; 95% CI, 1.80 to 4.87; p=0.001), and overall survival (HR, 2.13; 95% CI, 1.40 to 3.22; p=0.001). Conclusion Diabetic UTUC patients with poor preoperative glycemic control had significantly worse oncologic outcomes than diabetic UTUC patients with good preoperative glycemic control and non-diabetics. Further investigation is needed to elucidate the exact mechanism underlying the impact of glycemic control on UTUC treatment outcome. -
Citations
Citations to this article as recorded by- Development and validation of a prediction model for early recurrence in upper tract urothelial carcinoma treated with radical nephroureterectomy
Yi-Ju Chou, Hao-Lun Luo, Hung-Jen Wang, Steven K. Huang, Yu-Che Hsieh, Wen-Jeng Wu, Ching-Chia Li, Han-Yu Weng, Ta-Yao Tai, Chao-Hsiang Chang, Hsi-Chin Wu, Po-Hung Lin, Jacob See-Tong Pang, Chung-Hsin Chen, Jian-Hua Hong, Jen-Shu Tseng, Marcelo Chen, I-Hs
BMC Cancer.2025;[Epub] CrossRef - Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians
Laura Ashley, Saifuddin Kassim, Ian Kellar, Lisa Kidd, Frances Mair, Mike Matthews, Mollie Price, Daniel Swinson, Johanna Taylor, Galina Velikova, Jonathan Wadsley
BMJ Open.2022; 12(2): e060402. CrossRef - Annular-shaped stenosis in the ureter: Caution should be taken
Jie Ming, Yue Wang, Ziliang Su, Chunyang Wang
Urologic Oncology: Seminars and Original Investigations.2022; 40(6): 274.e7. CrossRef - Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis
Suping Ling, Michael Sweeting, Francesco Zaccardi, David Adlam, Umesh T. Kadam
BMC Cancer.2022;[Epub] CrossRef - Malnutrition management of hospitalized patients with diabetes/hyperglycemia and cancer cachexia
Rosa Burgos Peláez, José Pablo Suárez Llanos, Jose Manuel García Almeida, Pilar Matía Martín, Samara Palma Milla, Alejandro Sanz Paris, Ana Zugasti Murillo, Ana Artero-Fullana, Alfonso Calañas Continente, M.ª Jesús Chinchetru, Katherine García Malpartida,
Nutrición Hospitalaria.2022;[Epub] CrossRef - The Impact of Diabetes on the Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Xiaoshuai Gao, Liang Zhou, Jianzhong Ai, Wei Wang, Xingpeng Di, Liao Peng, Banghua Liao, Xi Jin, Hong Li, Kunjie Wang
Frontiers in Oncology.2021;[Epub] CrossRef - The Prognostic Value of Lymphovascular Invasion in Patients With Upper Tract Urinary Carcinoma After Surgery: An Updated Systematic Review and Meta-Analysis
Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Jun Yuan, Yejun Feng
Frontiers in Oncology.2020;[Epub] CrossRef - The impact of preoperative glycated hemoglobin levels on outcomes in oral squamous cell carcinoma
Ze Yun Tay, Huang‐Kai Kao, Kuang‐Hsu Lien, Shao‐Yu Hung, Yenlin Huang, Ngan‐Ming Tsang, Kai‐Ping Chang
Oral Diseases.2020; 26(7): 1449. CrossRef
- Development and validation of a prediction model for early recurrence in upper tract urothelial carcinoma treated with radical nephroureterectomy
- 13,571 View
- 122 Download
- 9 Web of Science
- 8 Crossref
First
Prev
